The relationship between monocyte/HDL cholesterol ratio and chronic kidney disease stages, single center study

Year 2023, , 9 - 12, 29.01.2023

İhsan Solmaz , Ömer Faruk Alakuş , Yusuf Yakut Yunus Tekin Sedrettin Koyun Eşref Araç

https://doi.org/10.56016/dahudermj.1193872

Abstract

Objectives: Chronic kidney disease (CKD) is an increasing public health problem. It is very important to know the definition of CKD, its risk factors and to predict the progression of its stages. Recently, the monocyte/HDL ratio (MHR) has been thought to be a new marker of inflammation and oxidative stress. In this study, it was aimed to investigate the relationship between stages and MHR in patients with stage 3A, stage 3B and stage 4 CKD.
Methods: A total of 632 patients with CKD, aged 18 years and older, with stage 3A, stage 3B and stage 4 (eGFR) according to CKD stage were included in our study. Our study is retrospective and the data of the patients were obtained from the hospital system. Kruskal-Wallis and post hoc Tukey HSD tests were used for statistics. p < 0.05 was considered statistically significant.
Results: The mean age of the patients included in the study was 63.4 ± 14.91(min:18max:98), and 305 (48.25%) of these patients were male and 327 (51.75%) were female. According to eGFR, 155 (24.5%) of the patients were stage 3A, 150 (23.8%) were stage 3B, and 327 (51.7%) were stage 4. In the statistical study of the groups divided into CKD stages with MHR, there was no significant difference between the groups (p: 0.245), while there was statistical significance for gender and hypertension (p: 0.004 and p: 0.044, respectively).
Conclusion: As a result of this study, we concluded that MHR is not affected by CKD stages.

Keywords

Monocyte-to-HDL ratio, Chronic kidney disease, Stage

References

• Hebert LA, ve ark. Renoprotection: One or many therapies? Kidney Int 59:1211-1226, 2001.
• Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res. 2004;95:764–772.
• Negi G, Kumar A, Joshi RP, et al. Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle. Biochem and Biophys Res Commun. 2011;408:1–5.
• You S, Zhong C, Zheng D, Xu J, Zhang X, Liu H et al. Monocyte to HDL cholesterol ratio is associated with discharge and 3-month outcome in patients with acute intracerebral hemorrhage. J Neurol Sci 2017; 372: 157-61.
• Karataş MB, Çanga Y, Özcan KS, Ipek G, Güngör B, Onuk T et al. Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with STEMI undergoing primary percutaneous coronary intervention. Am J Emerg Med 2016; 34(2): 240-4.
• Canpolat U, Aytemir K, Yorgun H, Şahiner L, Kaya EB, Çay S et al. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace 2015; 17(12): 1807-15.
• Canpolat U, Çetin EH, Cetin S, Aydin S, Akboga MK, Yayla C et al. Association of Monocyte-to-HDL Cholesterol Ratio with Slow Coronary Flow is Linked to Systemic Inflammation. Clin Appl Thromb Hemost 2016; 22(5): 476-82.
• Balta S, Celik T, Ozturk C, Kaya MG, Aparci M, Yildirim AO et al. The relation between monocyte to HDL ratio and noreflow phenomenon in the patients with acute ST-segment elevation myocardial infarction. Am J Emerg Med 2016; 34(8): 1542-7.
• Ancuta P, Wang J, Gabuzda D. CD16 + monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells . J Leukoc Biol 2006; 80(5): 1156-64.
• Hessler JR, Robertson AL, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979; 32(3): 213-29.
• Li XP, Zhao SP, Zhang XY, Liu L, Gao M, Zhou QC. Protective effect of high density lipoprotein on endothelium dependent vasodilatation. Int J Cardiol 2000; 73(3): 231-6.
• Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990; 1044(2): 275–83.
• Sözel Hasan, Avşar Esin, Alemdar Mustafa Serkan, Aydemir Mustafa Diyabetik süreçtemonosit/HDL kolesterol ve nötrofil/HDL kolesterol oranları. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, 2022;26(1):19 – 29
• Solmaz, I., & Karahan, M. (2021). Monocyte count / HDL cholesterol ratio: A new marker in diabetic retinopathy. Annals of Medical Research, 28(2), 0258–0260.
• Chen JW, Li C, Liu ZH, Shen Y, Ding FH, Shu XY et al. The role of monocyte to high-density lipoprotein cholesterol ratio in prediction of carotid intima-media thickness in patients with type 2 diabetes. Front Endocrinol (Lausanne) 2019; 10(4): 1– 11.
• Karatas A, Turkmen E, Erdem E, Dugeroglu H, Kaya Y. Monocyte to high-density lipoprotein cholesterol ratio in patients with diabetes mellitus and diabetic nephropathy. Biomark Med 2018; 12(9): 953–9.
• Onalan E. The relationship between monocyte to high-density lipoprotein cholesterol ratio and diabetic nephropathy. Pakistan J Med Sci 2019; 35(4): 1081–6.
• Pençe H. H. , Aktaş H. Ş. Diyabetik Nöropatisi Olan Kişilerde Monosit/HDL Kolesterol Oranı ile Kardiyovasküler Risk Arasındaki İlişki. OTSBD. 2019; 4(4): 526-538.